Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, with or without bevacizumab, for the treatment of adults with PD-L1+ (Combined Positive Score [CPS] ≥1), as determined by an FDA-authorized test, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma, who have received one or two prior systemic treatment regimens.
On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the weight-loss drug market. While the pharmaceutical giant reported a robust 9% increase in total revenue to $58.
Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the historic, yet short-lived, success of its Hepatitis C cures. However, as of early 2026, that narrative has shifted dramatically. Gilead has successfully executed a "second [...]
Merck’s fourth quarter was marked by continued demand for its oncology and cardiometabolic franchises, as well as the impact of several new product launches and strategic acquisitions. Management attributed growth to ongoing uptake of Keytruda in earlier-stage cancers and to strong animal health results. CEO Robert M. Davis highlighted that “successful new product launches, the advancement of important clinical programs, and the expansion of our respiratory and infectious disease portfolios through acquisitions” were key contributors. Challenges included lower vaccine sales in key Asian markets and margin declines due to increased investment in the business and higher inventory reserves.
In a week defined by high-stakes political theater and a brief but disruptive lapse in federal operations, Washington has managed to pull back from the edge of a total collapse—though only partially. On February 3, 2026, a $1.2 trillion appropriations package was signed into law, ending a four-day
In a move that underscores the pharmaceutical industry’s aggressive pivot toward integrated artificial intelligence, AstraZeneca (NASDAQ: AZN) recently announced the full acquisition of Modella AI, a Boston-based pioneer in multimodal foundation models and agentic software. The deal, finalized in January 2026 following a highly successful pilot partnership initiated in mid-2025, marks a watershed moment for [...]
The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a record-shattering $240 billion in total M&A investment in 2025, represents a fundamental shift in how
As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade ago, the British-Swedish multinational has transformed into a high-growth oncology and rare disease powerhouse. With a market capitalization now rivaling the [...]
The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes medicine Januvia.
In a decisive move to protect the nation’s multi-billion dollar livestock industry, U.S. Secretary of Agriculture Brooke Rollins announced today, February 5, 2026, the launch of a $100 million "New World Screwworm Grand Challenge." The federal initiative is designed to spur rapid innovation in the detection, containment, and
Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q4 CY2025, with sales up 5% year on year to $16.4 billion. On the other hand, the company’s full-year revenue guidance of $66.25 billion at the midpoint came in 2% below analysts’ estimates. Its non-GAAP profit of $2.04 per share was 1.5% above analysts’ consensus estimates.
Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 5% year on year to $16.4 billion. On the other hand, the company’s full-year revenue guidance of $66.25 billion at the midpoint came in 2% below analysts’ estimates. Its non-GAAP profit of $2.04 per share was 1.5% above analysts’ consensus estimates.
Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2025.
As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those struggling to navigate the steepest regulatory and patent hurdles in a generation. With major reports from Eli
The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative fervor surrounding a potential multi-billion-dollar acquisition of the company began to dissolve, leaving investors to grapple with a "news
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
